PMID- 22480223
OWN - NLM
STAT- MEDLINE
DCOM- 20130131
LR  - 20121130
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 136
IP  - 12
DP  - 2012 Dec
TI  - Correlation between histologic assessment and fluorescence in situ hybridization 
      using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions.
PG  - 1571-9
LID - 10.5858/arpa.2011-0673-OA [doi]
AB  - CONTEXT: The 4-probe, multicolor, fluorescence in situ hybridization (FISH) panel 
      targeting chromosomes 6 and 11 has shown promising sensitivity and specificity in 
      distinguishing between benign nevi and malignant melanoma. Only a few studies 
      have assessed the potential utility of FISH in classification of histologically 
      ambiguous melanocytic lesions. In the United States, this assay is exclusively 
      licensed to NeoGenomics Laboratories (Irvine, California), which provides the 
      technical component and has developed an innovative service (MelanoSITE) allowing 
      pathologists to interpret FISH results using a dedicated Web portal. Thus far, 
      use of MelanoSITE as a diagnostic adjunct in the diagnosis of melanocytic lesions 
      has not, to our knowledge, been reported in the literature. OBJECTIVE: To analyze 
      1.5 years of experience with the MelanoSITE melanoma FISH assay in the evaluation 
      of histologically ambiguous lesions in the context of second opinion and routine 
      dermatopathology practice. DESIGN: A prospective histologic/FISH correlation 
      study of 140 cases. RESULTS: Twenty-seven percent of abnormal FISH results were 
      false-positive results because of tetraploidy. After correcting for known 
      false-positive results, all lesions considered atypical nevi showed normal FISH 
      signals. Abnormal FISH signals were reported in 30% of lesions considered 
      histologically borderline and in 48% of lesions in which a diagnosis of melanoma 
      was favored. CONCLUSIONS: Four-probe, multicolor FISH results for melanoma 
      correlate with the microscopic assessments of histologically ambiguous lesions. 
      Pathologists using MelanoSITE must be aware of the high rate of false-positive 
      results from tetraploidy.
FAU - Zembowicz, Artur
AU  - Zembowicz A
AD  - Department of Pathology, Harvard Vanguard Medical Associates, Boston, 
      Massachusetts, USA. dr.z@DermatopathologyConsultations.com
FAU - Yang, Sung-Eun
AU  - Yang SE
FAU - Kafanas, Antonios
AU  - Kafanas A
FAU - Lyle, Stephen R
AU  - Lyle SR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120405
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Melanoma-Specific Antigens)
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Diagnosis, Differential
MH  - False Positive Reactions
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Materials Testing
MH  - Melanocytes/*metabolism/*pathology
MH  - Melanoma/*diagnosis/genetics/metabolism/pathology
MH  - Melanoma-Specific Antigens/metabolism
MH  - Middle Aged
MH  - Nevus/diagnosis/genetics/metabolism/pathology
MH  - Prospective Studies
MH  - *Reagent Kits, Diagnostic
MH  - Sensitivity and Specificity
MH  - Skin Neoplasms/*diagnosis/genetics/metabolism/pathology
MH  - Tetraploidy
MH  - Young Adult
EDAT- 2012/04/07 06:00
MHDA- 2013/02/01 06:00
CRDT- 2012/04/07 06:00
PHST- 2012/04/07 06:00 [entrez]
PHST- 2012/04/07 06:00 [pubmed]
PHST- 2013/02/01 06:00 [medline]
AID - 10.5858/arpa.2011-0673-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2012 Dec;136(12):1571-9. doi: 10.5858/arpa.2011-0673-OA. 
      Epub 2012 Apr 5.